{"id":994,"date":"1998-12-01T12:08:00","date_gmt":"1998-12-01T11:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu"},"modified":"1998-12-01T12:08:00","modified_gmt":"1998-12-01T11:08:00","slug":"vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/vertriebsstopp-fuer-tolcapon-tasmar-in-der-eu","title":{"rendered":"Vertriebsstopp f\u00fcr Tolcapon (Tasmar) in der EU"},"content":{"rendered":"<p>Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet 1998, 352, 958) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.AMB 1998, 32, 53a) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nach der Meldung von z.T. schweren Hepatitis-\u00e4hnlichen Nebenwirkungen mit zwei Todesf\u00e4llen (Assal, F., et al.: Lancet 1998, 352, 958) hat das Committee for Proprietary Medicinal Products (CPMP) der EMEA das Ruhen der Zulassung f\u00fcr das adjuvante Anti-Parkinsonmittel Tolcapon (s.a.AMB 1998, 32, 53a) beschlossen; die Mitgliedsl\u00e4nder wurden aufgefordert, den Vertriebsstopp ab dem 17. November 1998 anzuordnen. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1431],"class_list":["post-994","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-tolcapon"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=994"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/994\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}